Pharmaceutical Commerce - November/December 2009 - (Page 28)

executive Training & development People on the move Biopharma Orexigen Therapeutics (San Diego) has hired four executives as it files an NDA and other activities related to its obesity drug-development program. Dawn Viveash, MD, formerly of Amylin Pharmaceuticals, is head of global regulatory affairs. Suzanne McDonald, previously at Takeda Pharmaceuticals, is head of managed markets and government affairs. Preston Klassen, MD, previously at Amgen, will be head of the Contrave Program, for which an NDA is about to be submitted. Wendy Wang, PhD, MPH, is head of global biomedical information; previously, she was employed at Gilead Sciences. Oxford BioTherapeutics, a UK-based developer of oncology antibodies, has expanded the leadership of its San Jose, CA, US operations. Dr. Jim Cornett, with previous experience at Medarex, PDL and Centocor, will be the COO. Dr. John Terrett is VP of oncology; previously, he was employed at Medarex. In addition, Dr. Mike Gresser has been promoted to chief scientific offer, having worked at the company’s advisory board previously. at Xanodyne Pharmaceuticals, will be VP of sales. Amy Carvers, the new senior director of marketing, comes from Bristol-Myers Squibb. Linda Schock is director of commercial operations; previously, she worked at CV Therapeutics. The company is preparing the commercial launch of Qutenza, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions. Jazz Pharmaceuticals (Palo Alto, CA) has appointed Kathryn Falber at SVP and CFO, responsible for accounting, corporate finance, investor relations and treasury functions. Previously, she served as CFO and COO at ARCA BioPharma. Dr. Bruce Carter has joined Immune Design Corp. (Seattle) as executive chairman and director. Formerly, he was the CEO of Zymogenetics, and chief science officer at Novo Nordisk. Immune Design is developing vaccine products for infectious or malignant diseases. company has two subsidiaries, Ethex Corp. and Ther-Rx Corp. Inimex Pharmaceuticals (Burnaby, BC) has appointed Michael Abrams, PhD as president and CEO. He succeeds Dr. John Church, who will stay on as COO at the developer of immunoresponsive drugs. Service Providers Pegi Wieczorek has joined Altum, a full-service advertising and promotion company, as EVP, client services, with an emphasis on services to oncology accounts. Altum is a freestanding part of CommonHealth, a healthcare communications network. Wieczorek was previously the owner of Benefacta LLC, and has executive-level experience at both healthcare communications companies and pharma corporations, including Genentech and Pharmacia (now Pfizer). EMD Chemicals (Gibbstown, NJ) has promoted Deon Vos to named president and managing director, succeeding Meiken Krebs, who will become SVP of strategy at EMD’s German parent, Merck KGaA. Vos is moving from the managing director role at Merck (Pty) Ltd in South Africa. EMD is the North American chemicals sector of Merck KGaA, providing specialty chemicals for biopharma and other industries. SK&A Information Services (Irvine, CA) has promoted Jack Schember to VP of marketing, and has expanded the responsibilities of Albert Chang, VP of operations, to manage the SK&A Research Center. SK&A maintains a database of over two million healthcare professionals, including over 800,000 prescribers, for the biopharma industry. Schember, who has been with SK&A since 2006, has previous experience at Melissa Data, and direct and interactive marketing firms. Chang, completing his first year at SK&A, previously worked at Experian. Two executive appointments have been announced at Dohmen (Milwaukee): Kelli Kovak, chief development officer, and Michael Italiano, senior director, corporate development. Kovak, most recently SVP at Catalyst Medical Communications, is a registered pharmacist. Italiano has previous experience at Kimberly-Clark and Schwarz Pharma. Dohmen, a private company, has a outsourced services business, DDN, and a benefit management services company for payers, Restat. TAKE Supply Chain (formerly ClearOrbit, of Austin, TX) has hired Tom Hernandez as EVP, worldwide sales. Hernandez’ previous experience includes Infor-SSA Global and Peregrine Systems. Take Supply Chain, a subsidiary of TAKE Solutions, provides IT integration services for supply chain execution. With the retirement of Bob Whitney, GM at MD Logistics (Plainfield, IN), several promotions and appointments have been announced. Chad Hodges has been promoted to director of logistics services, and Tim Lawyer will replace Hodges as manager of shared logistics. Jeff Luthman has been appointed as VP of distribution operations, and John Sell as VP of freight forwarding and value-added services. MD Logistics provides logistics, inventory and fulfillment for industries including biopharma. West (Lionville, PA), a global manufacturer of components and systems for injectable drug delivery, has accepted the resignation of COO Matthew Mullarkey. Company president and former COO Steven Ellers will defer his previously announced retirement to provide managerial continuity, says the firm. Catalent Pharma Solutions (Somerset, NJ) has appointed Paul Burns as VP of global sales for the Somerset, NJ, formulation, packaging and manufacturing company. Previously, he was CEO of Brighter Ideas, Inc. a New Jersey biotech organization. JDSU has announced that Adam Scheer, its marketing director for the AOT Business segment, has been elected chairman of the International Hologram Manufacturer’s Assn., which represents the interests of hologram manufacturers worldwide. Saatchi & Saatchi Wellness (SSW) has promoted Ned Russel to EVP and managing director of the company, a New York-based division of Publicis Healthcare Communications continued on page 30 > www.PharmaceuticalCommerce.com The employment agreement with interim president and CEO of KV Pharmaceutical NeurogesX Inc. (San Mateo, CA) is expanding Co. (St, Louis), David Van Vliet, has been its commercial operations function with three extended to the end of 2011, the company’s appointments. Timothy1-2 page previously chairman, Page 1 Hatfield, announced. The Arendt, v2 21/10/09 09:18 Terry 05-03689 Global form The only event which brings together all stakeholders in the fight against counterfeit pharmaceuticals Pharmaceutical AntiCounterfeiting End-To-End Protection – from API to Patient Early-bird discounts available until 18 December Attended by pharma companies, regulators, health professionals, patients' groups, and anti-counterfeiting product and service providers. GLOBAL FORUM ON THE FIFTH February 24-26, 2010 Miami, Florida www.pharma-anticounterfeiting.info Exhibition and sponsorship opportunities available. Contact Reconnaissance International on info@reconnaissance-intl.com 28 NovemBer/deCemBer 2009 http://www.pharma-anticounterfeiting.info http://www.pharma-anticounterfeiting.info http://www.PharmaceuticalCommerce.com

Table of Contents for the Digital Edition of Pharmaceutical Commerce - November/December 2009

Pharmaceutical Commerce - November/December 2009
Contents
Editorial
Op-Ed
Top News
Business & Finance
Brand Marketing | Communications
SupplyChain | Logistics
Information Technology
Packaging & Drug Delivery
Legal | Regulatory
Executive Training & Development
Editorial Index | Meetings

Pharmaceutical Commerce - November/December 2009

https://www.nxtbook.com/nxtbooks/pharmcomm/202006
https://www.nxtbook.com/nxtbooks/pharmcomm/202003
https://www.nxtbook.com/nxtbooks/pharmcomm/201911
https://www.nxtbook.com/nxtbooks/pharmcomm/201909
https://www.nxtbook.com/nxtbooks/pharmcomm/201906
https://www.nxtbook.com/nxtbooks/pharmcomm/201903
https://www.nxtbook.com/nxtbooks/pharmcomm/201811
https://www.nxtbook.com/nxtbooks/pharmcomm/201809
https://www.nxtbook.com/nxtbooks/pharmcomm/201806
https://www.nxtbook.com/nxtbooks/pharmcomm/20180304
https://www.nxtbook.com/nxtbooks/pharmcomm/20171112
https://www.nxtbook.com/nxtbooks/pharmcomm/20170910
https://www.nxtbook.com/nxtbooks/pharmcomm/20170708
https://www.nxtbook.com/nxtbooks/pharmcomm/20170506
https://www.nxtbook.com/nxtbooks/pharmcomm/20170304
https://www.nxtbook.com/nxtbooks/pharmcomm/20170102
https://www.nxtbook.com/nxtbooks/pharmcomm/20161112
https://www.nxtbook.com/nxtbooks/pharmcomm/20160910
https://www.nxtbook.com/nxtbooks/pharmcomm/20160708
https://www.nxtbook.com/nxtbooks/pharmcomm/20160506
https://www.nxtbook.com/nxtbooks/pharmcomm/20160304
https://www.nxtbook.com/nxtbooks/pharmcomm/20160102
https://www.nxtbook.com/nxtbooks/pharmcomm/20151112
https://www.nxtbook.com/nxtbooks/pharmcomm/20150910
https://www.nxtbook.com/nxtbooks/pharmcomm/20150708
https://www.nxtbook.com/nxtbooks/pharmcomm/20150506
https://www.nxtbook.com/nxtbooks/pharmcomm/20150304
https://www.nxtbook.com/nxtbooks/pharmcomm/20150102
https://www.nxtbook.com/nxtbooks/pharmcomm/20141112
https://www.nxtbook.com/nxtbooks/pharmcomm/coldchaindirectory2014
https://www.nxtbook.com/nxtbooks/pharmcomm/20140910
https://www.nxtbook.com/nxtbooks/pharmcomm/20140708
https://www.nxtbook.com/nxtbooks/pharmcomm/20140506
https://www.nxtbook.com/nxtbooks/pharmcomm/20140304
https://www.nxtbook.com/nxtbooks/pharmcomm/20140102
https://www.nxtbook.com/nxtbooks/pharmcomm/dataservicedirectory
https://www.nxtbook.com/nxtbooks/pharmcomm/20131112
https://www.nxtbook.com/nxtbooks/pharmcomm/20130910_hubreport
https://www.nxtbook.com/nxtbooks/pharmcomm/20130910
https://www.nxtbook.com/nxtbooks/pharmcomm/20130708
https://www.nxtbook.com/nxtbooks/pharmcomm/20130506
https://www.nxtbook.com/nxtbooks/pharmcomm/coldchain2013
https://www.nxtbook.com/nxtbooks/pharmcomm/20130304
https://www.nxtbook.com/nxtbooks/pharmcomm/20130102
https://www.nxtbook.com/nxtbooks/pharmcomm/20121112
https://www.nxtbook.com/nxtbooks/pharmcomm/20120910
https://www.nxtbook.com/nxtbooks/pharmcomm/20120708
https://www.nxtbook.com/nxtbooks/pharmcomm/20120506
https://www.nxtbook.com/nxtbooks/pharmcomm/20120506_coldchain
https://www.nxtbook.com/nxtbooks/pharmcomm/20120304
https://www.nxtbook.com/nxtbooks/pharmcomm/20120102
https://www.nxtbook.com/nxtbooks/pharmcomm/20111112
https://www.nxtbook.com/nxtbooks/pharmcomm/20110910
https://www.nxtbook.com/nxtbooks/pharmcomm/20110708
https://www.nxtbook.com/nxtbooks/pharmcomm/20110506
https://www.nxtbook.com/nxtbooks/pharmcomm/20110304
https://www.nxtbook.com/nxtbooks/pharmcomm/20110102
https://www.nxtbook.com/nxtbooks/pharmcomm/20101112
https://www.nxtbook.com/nxtbooks/pharmcomm/20100910
https://www.nxtbook.com/nxtbooks/pharmcomm/20100708
https://www.nxtbook.com/nxtbooks/pharmcomm/20100506
https://www.nxtbook.com/nxtbooks/pharmcomm/201004
https://www.nxtbook.com/nxtbooks/pharmcomm/201003
https://www.nxtbook.com/nxtbooks/pharmcomm/20100102
https://www.nxtbook.com/nxtbooks/pharmcomm/20091112
https://www.nxtbookmedia.com